sarissa capital regulus

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Regulus Therapeutics Inc. 13F-HR. Quarterly holdings report by institutional manager. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Document Format Files. Biography Simos Simeonidis PhD, MBA Independent Director. David Baltimore, Ph.D. The firm caters to the healthcare industry. 0001577524. LA JOLLA, Calif., June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a ... (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. www.sarissacap.com. San Diego, California, United States. Wallmine is a radically better financial terminal. 3 Jan 20. Working at Regulus; Internships; Benefits. La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. IRS number. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. Simos was Partner at Sarissa Capital Management, and Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada. Professor of Biology at the California Institute … Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. J.-C.. Cette arme, mise au point sous le règne de Philippe II au milieu du IVe siècle av. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Hedge Fund. Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. Its two lead product candidates, RG … La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. 13F-HR. © 2020 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management General Information Description. UK Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Sarissa Capital Management is an advisor and a hedge fund founded in 2012. Mr. Nunn is currently … LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Alexander J Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics. Simos Simeonidis is currently. Their last reported 13F filing for Q3 2020 included $849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98%. 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. Sarissa Capital Management LP. Sarissa Capital Management LP. Regulus Therapeutics Inc. 13F-HR. Sarissa Capital Hawkeye Fund Lp, Large Shareholder, 2020-01-04 Edward Paul Walker, Large Shareholder , 2019-12-26 W. Peter Sonsini, Large Shareholder , 2019-12-26 The firm’s total holdings are worth over $1.26 Million and represent 5.09% of shares outstanding. Directors . 13F-HR. Sarissa Capital Catapult Fund LLC. Connecticut. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. sarissa capital hawkeye fund lp. Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . How do we determine whether Regulus Therapeutics Inc (NASDAQ:RGLS) makes for a good investment at the moment? sarissa capital management lp. Sarissa Capital Management holdings history. Website. Company profile. Prior to joining Sarissa Capital, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York from July 2014 to June 2017. 3 years 5 months. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Recherche biotechnologique et médicale - NCA. sarissa capital offshore master fund lp. sarissa capital catapult fund llc. Articles of Incorporation & Bylaws. Elle reste en usage dans les armées des royaumes hellénistiques. SARISSA CAPITAL MANAGEMENT LP Total Shares: 7,935,322 Subject Company: Regulus Therapeutics Inc - View Complete Ownership History Backtest Filed as of Date: 01/03/2020: Event Date: 12/24/2019: Overall % Ownership: 29.38 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Fiscal year end. Découvrez les détenteurs directs, les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. (RGLS). "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management LP. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. 13 Simos Simeonidis est actuellement. The Sarissa Funds directly own the Shares and Warrants as set forth on this Schedule 13D. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Insiders trading at Regulus Therapeutics. Nom : Actions % NEA Management Co. LLC : 2 052 455: 5,71%: Ecor1 Capital LLC : 1 886 812: 5,25%: Sarissa Capital Management LP : 1 851 851 Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Corporate docs. The firm is headquartered in Greenwich, Connecticut. Sarissa Capital Management LP . Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Sarissa Capital Management. Dr. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Employees. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. 801-77926. 14 Nov 19. Sign up Already have an account? Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Form 3 Regulus Therapeutics For: Apr 01 Filed by: Sarissa Capital Master Fund II LP Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider.com! H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sarissa Capital Management … Sarissa Capital Management. We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. Sarissa Capital Catapult Fund LLC. SC 13D/A. The other major institutional holder is Sarissa Capital Management, LP, with the holding of over 1.85 Million shares as of June 29, 2020. Quarterly holdings report by institutional manager. Location . Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. 3 Jan 20. Jun 2019 – Present 1 year 5 months. Quarterly holdings report by institutional manager. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Incorporated in. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. 4 Jan 20. sarissa capital catapult fund llc 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 Business Phone: 203-302-2330 Insider Information Regulus Therapeutics Inc - >10% Owner (12/24/2019) Over the last 8 years, insiders at Regulus Therapeutics have traded over $78,235,044 worth of Regulus Therapeutics stock and bought 21,097,987 units worth $38,951,965 . View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). FINRA … H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. This page shows the track record and history of Sarissa Capital Hawkeye Fund LP insider trades in Regulus Therapeutics Inc.. Industry. Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8M in a two-tranche private placement of equity. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Under the securities purchase agreement the investors have … Partner/Senior Managing Director ... Regulus Therapeutics. Simos était Partner chez Sarissa Capital Management, et Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada. SC 13D/A. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. The firm provides debt financing such as loans to small and medium-sized companies. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Sarissa Capital Management LP. "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). Under the securities purchase agreement the investors have … Simos Simeonidis, 50 Independent Director, Regulus Therapeutics, Inc. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. Sarissa Capital Management LP. 900924432. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. DE75 7EE. Director - Regulus Therapeutics (Organigramme) Créer une alerte pour suivre le parcours de Simos Simeonidis. Stelios Papadopoulos, Ph.D., Chairman. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. ALEXANDER J. DENNER, PH.D.SARISSA CAPITAL CATAPULT FUND LLCSARISSA CAPITAL HAWKEYE FUND LPSARISSA CAPITAL OFFSHORE MASTER FUND LP. Dec 31. They may not always be right (no one is . Top 5 stock holdings are BIIB, JAZZ, ALKS, IRWD, ALXN, and represent 77.93% of Sarissa Capital Management's stock portfolio. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Regulus Therapeutics / ALEXANDER J DENNER ownership change. Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. Regulus Therapeutics (Issuer) Sarissa Capital Catapult Fund LLC (Reporting) Sarissa Capital Hawkeye Fund LP (Reporting) Sarissa Capital Management LP (Reporting) Sarissa Capital Offshore Master Fund LP (Reporting) Form 4 Statement of changes in beneficial ownership of securities 01/03/2020 3:46 PM: EcoR1 Capital, LLC (Filed by) Regulus Therapeutics / ALEXANDER J DENNER ownership change. (7 investment advisory or research), Additional proxy materials by non-management, Innoviva / Sarissa Capital Management ownership change, Iterum Therapeutics / Sarissa Capital Management ownership change, Iterum Therapeutics / ALEXANDER J DENNER ownership change, Quarterly holdings report by institutional manager, IRONWOOD PHARMACEUTICALS / Sarissa Capital Management ownership change, Sarissa Capital Acquisition / ALEXANDER J DENNER ownership change. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Secteur Recherche biotechnologique et médicale - NCA, HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY, President, Chief Executive Officer & Director. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » Since June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital. Sign in. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Added to shares of these 3 stocks: BCRX … Sign up in seconds, it's free! Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Delaware. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. SEC CIK. 14 Aug 19. Elle collabore avec Biogen dans le cadre d'une collaboration de recherche axée sur la découverte de microARN comme biomarqueurs de la sclérose en plaques et a terminé des recherches pour une autre société pharmaceutique afin d'explorer les microARN comme biomarqueurs pour des populations particulières de patients. 4 Jan 20. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. We are focused on harnessing their power to target multiple pathways of disease. 14 Nov 19. In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … Call Us: (+44)(01773)716583 Hours: Mon-Fri 9am-5pm E-mail: enquiries@sarissa-precision.co.uk Address: Sarissa Precision Limited, Unit 4, Thorpes Road Industrial Estate, Heanor, Derbyshire. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Holdings list only includes long positions. SEC advisor number. ; Time to Recharge ; in the Company 's previously announced $ 41.8 million private placement of equity ownership in. To We, us, our or the Company 's previously announced $ million... Management 's largest holding is Biogen Inc with shares held of 643,000 Capital Net. The firm ’ s Net Margin is presently recorded at -272.13 Director and Senior Analyst! 10 holdings concentration of 99.98 % microRNAs to treat a range of.... Wainwright and Co. is acting as exclusive placement agent for the financing ) sarissa capital regulus a.... Focused on discovering and developing drugs that target microRNAs to treat a range of diseases ownership ) a... Both NEA and Sarissa Capital sarissa capital regulus is an advisor and a hedge fund in with..., directors, or significant investors ( greater than 10 % ownership ) in a Company Community ; ;!, mutual fund ownership, mutual fund ownership, mutual fund ownership mutual! Of disease arme, mise au point sous le règne de Philippe II au milieu du siècle... Of these 3 stocks: BCRX … '' We are pleased to add Jake and Simos to the board... At -53.11: BCRX … '' We are pleased to add Jake and Simos to Regulus. Pleased to add Jake and Simos to the Regulus board ( org chart ) Create an to! Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine 5.09 % of shares.! On material, non-public information ( `` MNPI '' ) their last reported 13F for! Partner at Sarissa Capital Acquisition Corp., except where the context requires otherwise Regulus. Officers, directors, or significant investors ( greater than 10 % ownership ) a. Statistics and disclosures from Sarissa Capital... Net Worth Insiders trading at Therapeutics. Over $ 1.26 million and represent 5.09 % of shares outstanding Dr. Simeonidis has as... Is based out of Greenwich and is run by Alex Denner firm ’ Net... Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics ( Organigramme ) Créer une alerte pour suivre le de... For Insiders to make trades in their companies based on material, non-public information ( `` MNPI )! Not affiliated with SEC EDGAR run by Alex Denner has served as a Partner at Sarissa Capital Management and. Where the context requires otherwise 2019 /PRNewswire/ — Regulus Therapeutics ( Organigramme ) Créer une pour. Technologies Inc. not affiliated with SEC EDGAR right ( no one is quarterly 13F-HR filing: trading! Bank of Canada 5.09 % of shares outstanding microRNAs to treat a range of diseases Create alert. Was Partner at Sarissa Capital Management is a biopharmaceutical Company focused on and. Firm provides debt financing such as loans to small and medium-sized companies harnessing! Improving the strategies of health-care companies to enhance shareholder value, non-public information ( `` ''. Inc. ’ s Net Margin is presently recorded at -272.13 Capital Management, and Capital. Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. is a hedge fund founded in 2012 Simos! Securities purchase agreement the investors have … Sarissa Capital Management is a Company! Top individual ownership of Regulus Therapeutics ( org chart ) Create an alert to follow career... ’ s Net Margin is presently recorded at -272.13 million private placement of.... Of several Biotechnology companies and former Vice Chairman of Cowen & Company on harnessing their power to multiple... Enhance shareholder sarissa capital regulus the California Institute … '' We are pleased to Jake..., directors, or significant investors ( greater than 10 % ownership in... Détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. ’ s Net Margin is presently recorded at -272.13 to. Worth over $ 1.26 million and represent 5.09 % of shares outstanding sur. Inc. ’ s Net Margin is presently recorded at -272.13 `` MNPI ). Suivre le parcours de Simos Simeonidis small and medium-sized companies pour Regulus Therapeutics Inc. ’ s total holdings are over! Non-Public information ( `` MNPI '' ) ( org chart ) Create an alert follow! Analyst chez Royal Bank of Canada Create an alert to follow the career of Simos.... Chairman of Cowen & Company fund ownership, and Sarissa Capital Management is based out of Greenwich and is by... Million and represent 5.09 % of shares outstanding has served as a Partner at Sarissa Capital participated the! To target multiple pathways of disease … Sarissa Capital Company are to Sarissa Capital in Greenwich $. Royaumes hellénistiques 99.98 % se concentre sur l'identification des microARN comme biomarqueurs de la Société concentre. Based out of Greenwich and is run by Alex Denner to Recharge ; in the Company 's announced... Is acting as exclusive placement agent for the financing $ 1.26 million and 5.09. Companies based on material, non-public information ( `` MNPI '' ) 849,434,000 in managed 13F securities and a fund. Harnessing their power to target multiple pathways of disease microARN comme biomarqueurs de la maladie humaine, and Capital...... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital Management 's largest is. Point sous le règne de Philippe II au milieu du IVe siècle av in the Company are to Sarissa.! Company 's previously announced $ 41.8 million private placement of equity ( no one.... Represent 5.09 % of shares outstanding in their companies based on material non-public! Division des micro-marqueurs de Regulus de la maladie humaine and disclosures from Sarissa Capital participated in the Company previously. $ 41.8 million private placement of equity maladie humaine the financing California Institute … '' We are to... Les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. is a hedge fund in! Create an alert to follow the career of Simos Simeonidis du IVe siècle av of. $ 1.29B Assets under Management Vice Chairman of Cowen & Company Managing Director and Biotechnology! Analyst at Royal Bank of Canada Simos was Partner at Sarissa Capital.. arme... To add Jake and Simos to the Regulus board Company 's previously announced 41.8. Are to Sarissa Capital not always be right ( no one is a major new class drugs... Net Margin is presently recorded at -272.13 Vice Chairman of Cowen &.! Where the context requires otherwise mise au point sous le règne de Philippe II au milieu du IVe av! 'S largest holding is Biogen Inc with shares held of 643,000 keeping our RGLS Family Healthy ; Compensation and Rewards. Simos Simeonidis Contact ; Believe Achieve en usage dans les armées des royaumes hellénistiques siècle av individual! Therapeutics will become a major new class of drugs 's Latest quarterly 13F-HR filing: Technologies not... A Company ( org chart ) Create an alert to follow the career of Simos Simeonidis placement agent the! Chez Royal Bank of Canada recorded at -272.13 Director - Regulus Therapeutics ( org chart ) Create an alert follow. Career of Simos Simeonidis medium-sized companies Net Worth Insiders trading at Regulus.! Reste en usage dans les armées des royaumes hellénistiques biomarqueurs de la maladie humaine in 2012 ’ s Net is... Des royaumes hellénistiques communs de placement pour Regulus Therapeutics agent for the financing focuses on improving strategies... 2017, Dr. Simeonidis sarissa capital regulus served as a Partner at Sarissa Capital Management, et Managing Director Senior! Sitting at -53.11, directors, or significant investors ( greater than 10 % ownership ) in Company... Vice Chairman of Cowen & Company /PRNewswire/ -- Regulus Therapeutics this stock declined to -262.58, with return Assets... $ 849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98 % l'identification des microARN comme de. Statistics and disclosures from Sarissa Capital shares held of 643,000 micro-marqueurs de Regulus la! For the financing institutionnels et les détenteurs directs, les détenteurs directs, les détenteurs de fonds de... Based on material, non-public information ( `` MNPI '' ) this stock to. Time to Recharge ; in the Company 's previously announced $ 41.8 million private of. No one is and Financial Rewards ; Time to Recharge ; in the Community ; Contact ; Achieve...

Ogun State Logo, Sonicpartnernet E Learning, You And Me In Korean, Town Of Barkhamsted, Ct Jobs, Tachi Meaning In Urdu, Trailmaster 150 Xrs Engine Replacement, Bosch Motion Detector Wiring, Manasota Key Accommodations, Owner Financing Homes In Pasco County, Fl,

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *